Chief Legal Officer of unprofitable biotech executes large mixed-direction trades: substantial purchases and sales totaling $1.5M on same day near 52-week highs.
Paul Varki, Avalo Therapeutics' Chief Legal Officer, executed a complex set of simultaneous buy and sell transactions totaling approximately $1.5 million—a significant portfolio activity for a C-suite officer. The timing is noteworthy: these trades occurred with the stock trading at its 52-week high after a sharp rally over recent months, not during a pullback where insider buying typically signals conviction. The company remains unprofitable with losses continuing, making this a high-risk environment where insider behavior is particularly illuminating. The mixed transaction pattern—buying while simultaneously selling at higher prices—suggests portfolio rebalancing or liquidity management rather than unambiguous conviction in the company's direction. For a CLO navigating regulatory and legal complexities at a cash-burning biotech, this activity warrants close attention to understand whether the net effect reflects confidence in turnaround prospects or prudent de-risking at an inflated valuation.